title: Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4.
abstract: Borreliacidal antibody production is one of several parameters for establishing the effectiveness of Borrelia burgdorferi vaccines. The production of borreliacidal antibody was studied in vitro by culturing immune lymph node cells with macrophages and B. burgdorferi. We showed that borreliacidal antibody, directed primarily against outer surface protein A (OspA), was readily produced by lymph node cells obtained from C3H/HeJ mice vaccinated with formalin-inactivated B. burgdorferi in aluminum hydroxide, but not recombinant OspA. Anti-OspA borreliacidal antibody was detected in supernatants of cultures of lymph node cells obtained on day 7 after vaccination, peaked on day 17, and rapidly declined. The borreliacidal activity was attributable to immunoglobulin G1 (IgG1), IgG2a, and IgG2b antibodies. When lymph node cells were treated with interleukin-4 (IL-4), production of borreliacidal antibody was inhibited but was unaffected by treatment with anti-IL-4 antibodies. These results suggest that other cytokines, but not IL-4, are mainly responsible for production of the secondary borreliacidal antibody response.
authors.affiliation: Wisconsin State Laboratory of Hygiene, University of Wisconsin, Madison, Wisconsin 53706, USA.
authors.forename: E L
authors.initials: EL
authors.lastname: Munson
authors.forename: B K
authors.initials: BK
authors.lastname: Du Chateau
authors.forename: D A
authors.initials: DA
authors.lastname: Jobe
authors.forename: S D
authors.initials: SD
authors.lastname: Lovrich
authors.forename: S M
authors.initials: SM
authors.lastname: Callister
authors.forename: R F
authors.initials: RF
authors.lastname: Schell
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000097:blood; D000954:Antigens, Surface / Q000276:immunology*; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D001428:Bacterial Vaccines / Q000276:immunology*; D015748:Borrelia burgdorferi Group / Q000276:immunology*; D002478:Cells, Cultured; D005557:Formaldehyde / Q000494:pharmacology; D015847:Interleukin-4 / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*; D008074:Lipoproteins; D008193:Lyme Disease / Q000517:prevention & control; D022123:Lyme Disease Vaccines / Q000276:immunology*; D008198:Lymph Nodes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D017737:Macrophages, Peritoneal / Q000166:cytology / Q000276:immunology; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D011994:Recombinant Proteins / Q000494:pharmacology; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D008074:Lipoproteins; D022123:Lyme Disease Vaccines; C072045:OspA protein; D011994:Recombinant Proteins; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic; D005557:Formaldehyde; D015847:Interleukin-4